BOSTON , Dec. 12, 2019 (GLOBE NEWSWIRE) -- Lead investigators from US and French Phase Ib/II clinical trials of APR-246 and Azacitidine (AZA) in patients with TP53 mutant MDS and AML, presented positive data on Monday at the 2019 ASH Annual Meeting. Both trials are evaluating the safety and

88% ORR , 61% CR rate by IWG criteria in 33 evaluable MDS patients 8.4 months median duration of response, with 7.3 months median duration of CR in evaluable MDS patients 52% of evaluable MDS patients discontinued treatment for stem cell transplant BOSTON , Dec.

BOSTON , Nov. 14, 2019 (GLOBE NEWSWIRE) -- Aprea Therapeutics , Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today reported financial results for the three and nine months

Company to host Clinical Update meeting and webcast on Monday, December 9 at 12:00 PM ET BOSTON , Nov. 06, 2019 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor

BOSTON , Oct. 07, 2019 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced the closing of its initial public offering of

BOSTON , Oct. 02, 2019 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. , a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced the pricing of its initial public offering of 5,666,667 shares

August 5, 2019 —BOSTON, MA. and STOCKHOLM, SWEDEN, August 5, 2019 – Aprea Therapeutics, a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein, today announced the appointment of Scott Coiante as

April 16, 2019 —BOSTON, MA. and STOCKHOLM, SWEDEN, April 16, 2019 – Aprea Therapeutics, a privately held, clinical stage biopharmaceutical company developing novel anticancer therapies targeting the tumor suppressor protein p53, today announced that the U.S.

April 3, 2019 —Studies support synergistic role of p53 stabilization by APR-246 in combination with immuno-oncology agents   BOSTON, MA. and STOCKHOLM, SWEDEN, April 3, 2019 – Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade

March 25, 2019 —BOSTON, MA. and STOCKHOLM, SWEDEN, March 25, 2019 – Aprea Therapeutics, a clinical-stage biotechnology company developing novel anticancer therapies targeting the p53 tumor suppressor protein, today announced the appointment of Dr. Eyal C.